Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology

儿童慈善医院儿科药理学合作奖学金计划

• 批准号: 10616748
• 负责人: Laura B Ramsey
• 金额: $ 23.19万
• 依托单位: CHILDREN'S MERCY HOSP (KANSAS CITY, MO)
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10616748
• 关键词: Child; Fellowship Program; Hospitals; pediatric pharmacology

Abstract The Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation at Children’s Mercy Hospital (CMH) in Kansas City, offers one of the largest, most diverse, Pediatric Clinical Pharmacology post-doctoral training programs in the U.S. It is constituted by 20 faculty including 1) clinicians cross-trained in Allergy/ Asthma/Immunology, Behavioral Medicine, Cardiology, Environmental/Occupational Health, Gastroenterology, Hematology/Oncology, Infectious Diseases, Maternal/Fetal Medicine, Neonatology, Nephrology, Nursing, Pharmacy, Rehabilitation Medicine, and Toxicology, along with 2) basic/translational scientists with experience in analytical chemistry, genetics, genomics, in vitro biotransformation, and molecular biology. Affiliated faculty contribute additional expertise in the areas of Bioethics, Bioinformatics, Health Outcomes, and Pharmaco- epidemiology. The program has made substantial contributions in the areas of pharmacogenetics, pharmaco- metrics, and early phase clinical trial design. The program combines robust didactic and experiential training in pharmacogenetics/genomics, metabolomics, pharmacometrics, pharmacoepidemiology, drug development, and the responsible conduct of research. It also offers unique elective opportunities dedicated to pediatric PBPK-based modeling and simulation (Simcyp/Certara), pediatric regulatory review and approval (FDA), bioinformatics (PharmGKB), Formulary management (CMH/Medicaid), and adult pharmacology (Mayo). Two independent Masters programs offered by affiliated medical schools round out the academic program at CMH. All teaching is accomplished by faculty with significant research experience in their respective subject areas. Trainees affiliate with the program for a minimum of three years; the first two years in Clinical Pharmacology are blended with the second and third years of their subspecialty training and their third year is dedicated to clinical pharmacology. Under the direction of a junior mentor, a senior mentor, and a scholarship oversight committee, fellows complete both a clinical and translational research project, produce several publications/ presentations, compete for a minimum of one research grant, and develop a plan to transition to independence prior to graduation. Quality is continually assured by a robust evaluation strategy and diversity is supported by a comprehensive recruitment strategy. Since its inception, the program at CMH has trained 24 pediatric clinical pharmacology fellows (17 pediatricians, 6 pharmacists, 1 nurse; 14 female, 2 African American, 1 Hispanic, 1 Native-American, 3 Asian) who during their fellowship period have collectively delivered 118 scientific presentations, prepared 102 peer-reviewed manuscripts and successfully competed for over $1,500,000 in intramural and extramural funding. The program is one of only three American Board of Clinical Pharmacology accredited training programs dedicated solely to Pediatric Clinical Pharmacology and its longstanding record of excellence provides applicants with unparalleled training in the discipline.

抽象的 儿童慈悲医院的临床药理学，毒理学和治疗创新部 （CMH）在堪萨斯城，提供了最大的，最潜水员，儿科临床药理学后的博士学位。 美国的培训计划由20位教师组成，其中包括1）在过敏/ 哮喘/免疫学，行为医学，心脏病学，环境/职业健康，胃肠病学， 血液学/肿瘤学，传染病，孕产妇/胎儿医学，新生儿学，肾脏病，护理， 药房，康复医学和毒理学，以及2）具有经验的基本/转化科学家 在分析化学，遗传学，基因组学，体外生物转化和分子生物学中。会员教师 在生物伦理学，生物信息学，健康成果和药物方面贡献更多的专业知识 流行病学。该计划在药物遗传学，药物 - 指标和早期临床试验设计。该计划结合了强大的教学和经验丰富的培训 药物遗传学/基因组学，代谢组学，药物电子学，药物开发， 以及负责任的研究。它还提供了专门针对儿科的独特选修机会 基于PBPK的建模和仿真（SIMCYP/CERTARA），儿科监管审查和批准（FDA）， 生物信息学（PharmGKB），配方管理（CMH/Medicaid）和成人药理学（Mayo）。二 会员医学院提供的独立硕士课程在CMH上为学术课程提供了核对。 所有教学都是通过在各自学科领域具有丰富研究经验的教师来完成的。 学员的附属计划至少三年；临床药理学的头两年 与他们的第二年培训的第二年和第三年混合，他们的第三年致力于 临床药理学。在大三的精神，高级精神和奖学金监督的指导下 委员会既完成临床和翻译研究项目，又有几个出版物/ 演讲，竞争至少一项研究赠款，并制定了过渡到独立的计划 毕业前。强大的评估策略不断地假设质量，并且多样性得到了支持 全面的招聘策略。自成立以来，CMH的计划已培训了24个小儿临床 药理学研究员（17名儿科医生，6名药剂师，1名护士； 14名女性，2名非裔美国人，1个西班牙裔，1个 在他们的奖学金期间，他共同交付了118个科学 演讲，准备了102个同行评审的手稿，并成功竞争了超过$ 1,500,000 壁内和壁外资金。该计划是美国临床药理学委员会仅有的三个计划之一 认可的培训计划专门专门用于儿科临床药理学及其长期记录 卓越为该学科的培训提供了无与伦比的培训。

项目成果

Deep Brain Stimulation for Pediatric Dystonia: A Review of the Literature and Suggested Programming Algorithm.

• DOI: 10.1177/08830738221115248
• 发表时间: 2022-10
• 期刊: Journal of child neurology
• 影响因子: 1.9

Examining the role of precision medicine with oral baclofen in pediatric patients with cerebral palsy.

检查口服巴氯芬的精准医疗对脑瘫儿科患者的作用。

• 发表时间: 2019
• 期刊: Current physical medicine and rehabilitation reports
• 影响因子: 1.1
• 作者: McLaughlin,MatthewJ;Abdel-Rahman,Susan;Leeder,JSteven
• 通讯作者: Leeder,JSteven

Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.

• DOI: 10.1016/j.pmrj.2017.08.441
• 发表时间: 2018-03
• 期刊: PM & R : the journal of injury, function, and rehabilitation
• 作者: McLaughlin MJ;He Y;Brunstrom-Hernandez J;Thio LL;Carleton BC;Ross CJD;Gaedigk A;Lewandowski A;Dai H;Jusko WJ;Leeder JS
• 通讯作者: Leeder JS

Missed Opportunities and the Impact of the Pandemic.

• DOI: 10.1097/dbp.0000000000001065
• 发表时间: 2022-04-01
• 期刊: JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
• 影响因子: 2.4
• 作者: Sabapathy, Thusa;Bansal, Riya;Bojorquez, Lauren;Salley, Brenda;Gianakon, Julie Grace;Gelineau-Morel, Rose;Nyp, Sarah S.
• 通讯作者: Nyp, Sarah S.

Decreased Pregnane X Receptor Expression in Children with Active Crohn's Disease.

• DOI: 10.1124/dmd.115.068742
• 发表时间: 2016-07
• 期刊: Drug metabolism and disposition: the biological fate of chemicals
• 作者: Shakhnovich V;Vyhlidal C;Friesen C;Hildreth A;Singh V;Daniel J;Kearns GL;Leeder JS
• 通讯作者: Leeder JS